Drugs / Sodium Enoxaparine
Sodium Enoxaparine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02368314 | Jan → Dec 2015 | venous thromboembolism | Biocad | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sodium Enoxaparine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02368314 ↗ |
| Known as | BCD-080 (Sodium Enoxaparine) | “BCD-080 (Sodium Enoxaparine)” NCT02368314 ↗ |
| Known as | Clexane (Sodium Enoxaparine) | “Clexane (Sodium Enoxaparine)” NCT02368314 ↗ |
| Route | Subcutaneous | “30 mg (0,3 ml), subcutaneously, twice a day (every 12 h).” NCT02368314 ↗ |